Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 13, 2026
Moleculin Biotech, Inc. (MBRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $7.6 million. As of Jun 30, 2026 it held $7.3 million in cash and investments and $292,000 in total debt.
Revenue
$0
Net income
$-7.63M
+57.1% vs year-ago quarter
Operating cash flow
$-6.66M
-19.3% vs year-ago quarter
Free cash flow
$-5.37M
-5.6% vs year-ago quarter
EPS
—
Dividend per share
None
Shares outstanding
19.48M
-35.7% vs year-ago quarter
Net cash
$6.97M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MBRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1659617
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$7.6M | -$7.9M | -$7.5M | -$5.9M | -$5.7M |
| Net income | -$7.6M | -$12.8M | $15.6M | -$25.4M | -$17.8M |
| Operating cash flow | -$6.7M | -$6.1M | -$5.4M | -$7.2M | -$5.6M |
| Free cash flow | — | — | -$5.4M | -$7.2M | -$5.6M |
| Total assets | $21.1M | $23.4M | $22.1M | $20.4M | $21.6M |
| Total liabilities | $9.5M | $8.2M | $7.1M | $47.3M | $25.2M |
| Stockholders' equity | $11.6M | $15.2M | $15.0M | -$26.9M | -$3,585 |
| Cash and investments | $7.3M | $10.3M | $8.9M | $6.7M | $7.6M |
| Total debt | $292,000 | $326,000 | $359,000 | $390,000 | $420,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 30, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Oct 20, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 16, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 5, 2026 | Oct 5, 2026 |
All 838 Moleculin Biotech, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.